ArticleNPJ vaccines2025
Exploratory evidence of mitigated immune imprinting following concomitant COVID-19 and influenza vaccination.
Article in NPJ vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Concomitant administration of coronavirus disease (COVID-19) and influenza vaccination schedules has been widely adopted. However, long-term data on the immunological impact, particularly on variant-specific responses, remain limited. In this 10-month prospective study, 80 participants (40 per group) received either a concomitant bivalent COVID-19 mRNA booster and quadrivalent influenza vaccination (Group C) or separate vaccinations (Group S) at least 4 weeks apart. Immunogenicity was evaluated using an anti-S IgG electrochemiluminescence immunoassay, anti- receptor-binding domain (RBD) IgG enzyme-linked immunosorbent assay, focus reduction neutralisation test (FRNT), and hemagglutination-inhibition assay. Both Groups C and S elicited robust immune responses for up to 10 months with no immune interference, as antibody responses against wild-type (WT) and Omicron BA.5 remained comparable between the groups. Notably, neutralising antibody titre against Omicron BA.5 were higher in Group C at 1 month post-vaccination, with significantly higher neutralising potency (FRNT
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.